Table 1. Clinical and pathological features of the study population.
| Variance | No.(%) of patients | |||||
|---|---|---|---|---|---|---|
| R0 resection (n= 272) | Primary resection(n= 4025) | Metastases resection(n= 409) | No resection(n= 5735) | Total(n= 10441) | P value | |
| Age | <0.001 | |||||
| ≤45years | 56 (20.6) | 713 (17.7) | 67 (16.4) | 664 (11.6) | 1500 (14.4) | |
| >45years | 216 (79.4) | 3312 (82.3) | 342 (83.6) | 5071 (88.4) | 8941 (85.6) | |
| Race | 0.025 | |||||
| White | 222 (81.6) | 3098 (77.0) | 322 (78.7) | 4363 (76.1) | 8005 (76.7) | |
| Black | 33 (12.1) | 622 (15.5) | 64 (15.6) | 989 (17.2) | 1708 (16.4) | |
| Other | 15 (5.5) | 296 (7.4) | 22 (5.4) | 359 (6.3) | 692 (6.6) | |
| Unknown | 2 (0.7) | 9 (0.2) | 1 (0.2) | 24 (0.4) | 36 (0.3) | |
| Grade | <0.001 | |||||
| Well | 19 (7.0) | 262 (6.5) | 19 (4.6) | 284 (5.0) | 584 (5.6) | |
| Moderate | 98 (36.0) | 1291 (32.1) | 87 (21.3) | 1460 (25.5) | 2936 (28.1) | |
| Poor | 121 (44.5) | 2146 (53.3) | 96 (23.5) | 1867 (32.6) | 4230 (40.5) | |
| Unknown | 34 (12.5) | 326 (8.1) | 207 (50.6) | 2124 (37.0) | 2691 (25.8) | |
| Stage T | <0.001 | |||||
| T0 | 5 (1.8) | 4 (0.1) | 32 (7.8) | 165 (2.9) | 206 (2.0) | |
| T1 | 55 (20.2) | 611 (15.2) | 44 (10.8) | 436 (7.6) | 1146 (11.0) | |
| T2 | 84 (30.9) | 1382 (34.3) | 69 (16.9) | 950 (16.6) | 2485 (23.8) | |
| T3 | 35 (12.9) | 610 (15.2) | 21 (5.1) | 474 (8.3) | 1140 (10.9) | |
| T4 | 71 (26.1) | 1217 (30.2) | 96 (23.5) | 1984 (34.6) | 3368 (32.3) | |
| Tx | 22 (8.1) | 201 (5.0) | 147 (35.9) | 1726 (30.1) | 2096 (20.1) | |
| Stage N | <0.001 | |||||
| 0 | 56 (20.6) | 787 (19.6) | 100 (24.4) | 1271 (22.2) | 2214 (21.2) | |
| 1 | 80 (29.4) | 1308 (32.5) | 116 (28.4) | 1956 (34.1) | 3460 (33.1) | |
| 2 | 51 (18.8) | 745 (18.5) | 21 (5.1) | 347 (6.1) | 1164 (11.1) | |
| 3 | 58 (21.3) | 877 (21.8) | 30 (7.3) | 502 (8.8) | 1467 (14.1) | |
| NX | 27 (9.9) | 307 (7.7) | 142 (34.7) | 1659 (28.9) | 2136 (20.5) | |
| Radiation | <0.001 | |||||
| Done | 135 (49.6) | 1703 (42.3) | 163 (39.9) | 1685 (29.4) | 3686 (35.5) | |
| None | 127 (46.7) | 2216 (55.1) | 219 (53.5) | 3979 (69.4) | 6541 (62.6) | |
| Unknown | 10 (3.7) | 106 (2.6) | 27 (6.6) | 71 (1.2) | 214 (2.0) | |
| ER | <0.001 | |||||
| Positive | 180 (66.2) | 2589 (64.3) | 248 (60.6) | 3403 (59.3) | 6420 (61.5) | |
| Negative | 75 (27.6) | 1156 (28.7) | 78 (19.1) | 1241 (21.6) | 2550 (24.4) | |
| Unknown | 17 (6.3) | 280 (7.0) | 83 (20.3) | 1091 (19.0) | 1471 (14.1) | |
| PR | <0.001 | |||||
| Positive | 148 (54.4) | 1990 (49.4) | 172 (42.1) | 2574 (44.9) | 4884 (46.8) | |
| Negative | 104 (38.2) | 1706 (42.4) | 144 (35.2) | 1953 (34.1) | 3907 (37.4) | |
| Unknown | 20 (7.4) | 329 (8.2) | 93 (22.7) | 1208 (21.1) | 1650 (15.8) | |
| HR | <0.001 | |||||
| HR+ | 184 (67.6) | 2646 (65.7) | 252 (61.6) | 3472 (60.5) | 6554 (62.8) | |
| HR- | 70 (25.7) | 1095 (27.2) | 74 (18.1) | 1162 (20.3) | 2401 (23.0) | |
| Unknown | 18 (6.6) | 284 (7.1) | 83 (20.3) | 1101 (19.2) | 1486 (14.2) | |
| Metastatic site | <0.001 | |||||
| Distant Lymph node | 48 (17.6) | 334 (8.3) | 22 (5.4) | 192 (3.3) | 596 (5.7) | |
| Designated organsa | 94 (34.6) | 1709 (42.5) | 167 (40.8) | 2393 (41.7) | 4363 (41.8) | |
| Other organs | 78 (28.7) | 1541 (38.3) | 130 (31.8) | 2164 (37.7) | 3913 (37.5) | |
| Multipleb | 44 (16.2) | 373 (9.3) | 81 (19.8) | 913 (15.9) | 1411 (13.5) | |
| Unknown | 8 (2.9) | 68 (1.7) | 9 (2.2) | 73 (1.3) | 158 (1.5) | |
HR+ was defined as ER+ or PR+. HR- was defined as both ER- and PR-.
a
Designated organs, metastasis in the following organs: adrenal (suprarenal) gland, bone, other than the adjacent rib, contralateral (opposite) breast, lung, ovary, satellite nodule(s) in skin other than the primary breast.
b
Multiple mean metastases in at least two of the above sites.